MICROLIN BIO, INC Financial Statements (2025 and earlier)
Company Profile
| Business Address |
135 EAST 57TH STREET, 24TH FLOOR NEW YORK, NY 10022 |
| State of Incorp. | DE |
| Fiscal Year End | September 30 |
| Industry (SIC) | 65 - Real Estate (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 2 | 7 | |||
| Cash and cash equivalent | 2 | 7 | |||
| Receivables | 1 | ||||
| Prepaid expense | 94 | ||||
| Total current assets: | 3 | 101 | |||
| Noncurrent Assets | |||||
| TOTAL ASSETS: | 3 | 101 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 11 | 16 | |||
| Other undisclosed accounts payable and accrued liabilities | 11 | 16 | |||
| Debt | 23 | 31 | |||
| Due to related parties | 9 | ||||
| Total current liabilities: | 43 | 48 | |||
| Noncurrent Liabilities | |||||
| Total liabilities: | 43 | 48 | |||
| Equity | |||||
| Equity, attributable to parent, including: | (40) | 54 | |||
| Common stock | 9 | 9 | |||
| Common stock, value, subscriptions | 32 | ✕ | |||
| Additional paid in capital | 261 | 163 | |||
| Accumulated deficit | (342) | ||||
| Other undisclosed equity, attributable to parent | (119) | ||||
| Total equity: | (40) | 54 | |||
| TOTAL LIABILITIES AND EQUITY: | 3 | 101 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|
| Revenues | 8 | |||
| Cost of revenue (Cost of Product and Service Sold) | (4) | (3) | ||
| Gross profit: | 5 | (3) | ||
| Operating expenses | (137) | (77) | ||
| Other operating expense, net | (15) | (31) | ||
| Operating loss: | (147) | (111) | ||
| Nonoperating income (Debt Instrument, Convertible, Beneficial Conversion Feature) | 32 | 125 | ||
| Interest and debt expense | 140 | 31 | ||
| Income from continuing operations before equity method investments, income taxes: | 24 | 45 | ||
| Other undisclosed loss from continuing operations before income taxes | (258) | (153) | ||
| Loss from continuing operations before income taxes: | (234) | (108) | ||
| Income tax expense | (34) | |||
| Loss from continuing operations: | (267) | (108) | ||
| Loss before gain (loss) on sale of properties: | (267) | (108) | ||
| Other undisclosed net income | 44 | |||
| Net loss available to common stockholders, diluted: | (224) | (108) | ||
Comprehensive Income ($ in thousands)
| 9/30/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|
| Net loss: | (224) | (108) | ||
| Comprehensive loss, net of tax, attributable to parent: | (224) | (108) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.